1/ This week in #IDTwitter Alice Han asked a great question about meropenem-resistant Strep pneumo.

UNMC ID ASP recently had a similar question when looking at our antibiogram.

So I did a mini-lit review in the form of a #Tweetorial

/thread

twitter.com/dralicehan/sta…

I have spoken about “usual care” or “treatment as usual” as a control arm in trials before, but should you ever protocolise usual care or just measure it as is? 1/8
#MethodologyMonday #77

Sick of your IRB/Ethics Committee insisting on lengthy patient information for enrolment into clinical trials? FDA has new draft guidance which will make life much easier for investigators and potential participants! fda.gov/news-events/fd…

New #ARLGNetwork study published in Clinical Infectious Diseases analyzed participant demographic reporting and subgroup representation in 20 years of trial data for antibacterials used to treat Staphylococcus aureus infections. Read more here: bit.ly/42oGkdW

💥 Which trial…? Clinical Microbiology and Infection This one’s an old #IDTwitter favourite! With Steven Tong & a 🌟 cast. Trials like this are worth doing, “not because they are easy, but because they are hard.” 🚀 🌕 Here are a few thoughts on how we might do it 😊 (A. TOGETHER!) doi.org/10.1016/j.cmi.…

🆕️🔥 Clinical Infectious Diseases Melissa Hardy Patrick Harris David Paterson
Win ratio analyses of pip-tazo Vs meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO Trial #IDXposts
academic.oup.com/cid/advance-ar…

Do clinical trials of antimicrobial agents give clinicians the information they need in order to change guidelines and revise their prescribing patterns?
A thread on a new way to analyze clinical trial results